LESLIE GASSER: Open Payments
NPI 1104494442 · EVANSVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$442 in 28 payments from 13 companies in 2025. Trend: 2023 $1,567 · 2024 $2,004 · 2025 $442
Food & beverage: $442
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $136 |
| Otsuka America Pharmaceutical, Inc. | 3 | $52 |
| Janssen Biotech, Inc. | 2 | $42 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Novo Nordisk Inc | 2 | $33 |
| Vanda Pharmaceuticals Inc. | 1 | $22 |
| Tris Pharma Inc | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $17 |
Products named: QULIPTA, REXULTI, TREMFYA, AIRSUPRA, Ozempic, MAVYRET, UBRELVY, HETLIOZ.
Industry payments across IN — which companies pay providers there.
